Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marie Helleberg

Showing results (141-150 of 148) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 148 results.
The Journal of Infectious Diseases|September 13, 2024
Evaluation of the Feasibility and Efficacy of Point-of-Care Antibody Tests for Biomarker-Guided Management of Coronavirus Disease 2019Cavan Reilly, Eleftherios Mylonakis, Robin Dewar, et al.
Acta Anaesthesiologica Scandinavica|August 12, 2020
Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-Protocol and statistical analysis planMarie Warrer Petersen, Tine Sylvest Meyhoff, Marie Helleberg, et al.
Acta Anaesthesiologica Scandinavica|February 14, 2021
Higher vs lower doses of dexamethasone in patients with COVID-19 and severe hypoxia (COVID STEROID 2) trial: Protocol and statistical analysis planM W Munch, Anders Granholm, S N Myatra, et al.
Acta Anaesthesiologica Scandinavica|February 14, 2021
Higher vs Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia (COVID STEROID 2) trial: Protocol for a secondary Bayesian analysisAnders Granholm, Marie Warrer Munch, Sheila Nainan Myatra, et al.
Intensive Care Medicine|November 10, 2021
Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trialAnders Granholm, Marie Warrer Munch, Sheila Nainan Myatra, et al.
Intensive Care Medicine|April 1, 2022
Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemiaAnders Granholm, Maj-Brit Nørregaard Kjær, Marie Warrer Munch, et al.
Acta Anaesthesiologica Scandinavica|June 17, 2021
Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: The COVID STEROID randomised, placebo-controlled trialMarie Warrer Munch, Tine Sylvest Meyhoff, Marie Helleberg, et al.
JAMA|October 21, 2021
Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial, Marie W Munch, Sheila N Myatra, et al.
Pageof 15

Showing results (141-150 of 148) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 148 results.
The Journal of Infectious Diseases|September 13, 2024
Evaluation of the Feasibility and Efficacy of Point-of-Care Antibody Tests for Biomarker-Guided Management of Coronavirus Disease 2019Cavan Reilly, Eleftherios Mylonakis, Robin Dewar, et al.
Acta Anaesthesiologica Scandinavica|August 12, 2020
Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-Protocol and statistical analysis planMarie Warrer Petersen, Tine Sylvest Meyhoff, Marie Helleberg, et al.
Acta Anaesthesiologica Scandinavica|February 14, 2021
Higher vs lower doses of dexamethasone in patients with COVID-19 and severe hypoxia (COVID STEROID 2) trial: Protocol and statistical analysis planM W Munch, Anders Granholm, S N Myatra, et al.
Acta Anaesthesiologica Scandinavica|February 14, 2021
Higher vs Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia (COVID STEROID 2) trial: Protocol for a secondary Bayesian analysisAnders Granholm, Marie Warrer Munch, Sheila Nainan Myatra, et al.
Intensive Care Medicine|November 10, 2021
Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trialAnders Granholm, Marie Warrer Munch, Sheila Nainan Myatra, et al.
Intensive Care Medicine|April 1, 2022
Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemiaAnders Granholm, Maj-Brit Nørregaard Kjær, Marie Warrer Munch, et al.
Acta Anaesthesiologica Scandinavica|June 17, 2021
Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: The COVID STEROID randomised, placebo-controlled trialMarie Warrer Munch, Tine Sylvest Meyhoff, Marie Helleberg, et al.
JAMA|October 21, 2021
Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial, Marie W Munch, Sheila N Myatra, et al.
Pageof 15